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Abstract The behavioral effects induced by central administra-
tion in mice of the endogenous ORLj (opioid receptor-like]) 
ligand, nociceptin/orphanin FQ, were investigated in the absence 
or presence of inhibitors of aminopeptidase N (bestatin) and 
endopeptidase 24.15 (Z-(L!D)PheT(P02CH2)(L,D)Ala-Arg-Phe) 
recently shown to be involved in the metabolism of the 
heptadecapeptide in vitro. A severe reduction in motor activity 
induced by nociceptin/orphanin FQ was measured in two tests 
(spontaneous motor activity and open field). This pharmacolog-
ical effect was shown to be potentiated by the association of 
bestatin and Z-(LiD)PheT(P02CH2)(L,D)Ala-Arg-Phe, confirm-
ing in vivo the involvement of these peptidases in nociceptin/ 
orphanin FQ inactivation. In our conditions, these inhibitors were 
devoid of intrinsic effects, suggesting a low tonic regulation by 
the heptadecapeptide of the measured behaviour. 
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1. Introduction 
In addition to the three major types of opioid receptors, μ, 
δ and κ (review in [1]), a novel receptor (ORLi, opioid recep-
tor-likei) was identified on the basis of its homology with the 
amino acid sequence of opioid receptors [2-8]. The ORLi 
receptor has a very low affinity for traditional opioid peptides 
(dynorphins, endorphins, and enkephalins). Two groups have 
recently isolated a heptadecapeptide, nociceptin/orphanin FQ, 
FGGFTGARKSARKLANQ [9,10], structurally resembling 
dynorphin A, and which behaves as a potent endogenous 
ligand of the ORLi receptor. As expected, nociceptin/orpha-
nin FQ exhibits a nanomolar affinity for the ORLi receptor 
and a low affinity for the μ, δ, κ opioid receptors despite the 
presence in N-terminal position of the FGGF sequence in-
stead of YGGF in endogenous opioid receptor ligands. 
Although the functional role of nociceptin/orphanin FQ re-
mains unknown, the wide distribution of ORLi mRNA and 
nociceptin/orphanin FQ precursor in the central nervous sys-
tem of rodents, particularly in the limbic system and in several 
areas known to be involved in the control of nociceptive stim-
uli, including the spinal cord dorsal horn, have suggested that 
this peptide could be involved in pain perception [2-5,11-13]. 
The peptide has been reported to heighten sensitivity to pain 
following i.c.v. injection in mice but to be without effect after 
spinal application [9,10]. Nevertheless, a recent study dis-
agrees with these results, showing that nociceptin/orphanin 
FQ has an inhibitory action on spinal dorsal horn neurones 
in rat [14]. Furthermore nociceptin/orphanin FQ was reported 
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to decrease motor activity and to reduce the muscular tone of 
mice [10]. 
As clearly shown with the enkephalins, the interruption of 
peptidergic signals is ensured by peptidase-induced inactiva-
tion of the endogenous peptide effector (review in [15]). We 
have recently shown by using brain slices that nociceptin/or-
phanin FQ is hydrolysed essentially at its Phe^Gly2 and 
Ala7-Arg8 peptide bonds by aminopeptidase N (APN) and 
endopeptidase 3.4.24.15 [16]. The biological relevance of this 
metabolic pathways was confirmed in this study by measuring 
the behavioral effects induced by i.c.v. administration in mice 
of nociceptin/orphanin FQ, or the metabolite peptides Gly2-
Gln17 and Phe1-Ala7 in the absence or in the presence of 
aminopeptidase and endopeptidase 24.15 inhibitors. Thus, 
these compounds potentiated the severe impairment in motor 
activity induced by the heptadecapeptide. 
2. Materials and methods 
2.1. Chemicals 
Nociceptin/orphanin FQ and metabolite peptides were synthesized 
using the stepwise solid-phase method of Merrifield [17] on a Applied 
Biosystems model 431A automated peptide synthesizer with Applied 
Biosystems small-scale Fmoc chemistry. Peptides were cleaved from 
the resin, deprotected, diethyl ether-precipitated, and washed in ac-
cordance with Applied Biosystems guidelines. All the peptides were 
purified by reverse-phase HPLC on a Vydac Ci8 column (250x10 
mm) using acetonitrile gradients in 0.1% trifluoroacetic acid. Bestatin 
was purchased from Roger Bellon (France), and the selective endo-
peptidase 24.15 inhibitor [Z-(L>D)Phe
<l'(P02CH2)(L,D)Ala-Arg-Phe] 
was kindly provided by Dr. V. Dive (Commisariat ä l'Energie Ato-
mique, Centre d'Etudes Nucleaires de Saclay, Saclay, France). Noci-
ceptin/orphanin FQ, metabolite peptides, and peptidase inhibitors 
were dissolved in saline. 
2.2. Animals 
Animals used in this study were acquired, cared for and used in 
accordance with the guidelines published in the European Commu-
nities Council directives (86/609/EEC). 
Male CDi mice (20-22 g) were obtained from Charles River France 
(Saint-Aubin-Les-Elbeuf, France). Animals were supplied with food 
and water ad libitum and housed in groups (n = 20) in an environment 
controlled for both temperature (22 ± 1°C) and humidity (45-55%) at 
least 2 days before the experiments were started. All behavioral meas-
ures were recorded between 10:00 h and 20:00 h. 
2.3. Intracerebroventricular and systemic injections 
Nociceptin/orphanin FQ, metabolite peptides, and peptidase inhib-
tors were injected free hand in the left lateral ventricule (i.c.v.) 15 min 
before the open field. The antagonist naloxone was administered s.c. 
5 min before i.c.v. injection. 
2.4. Behavioral tests 
The open field was a rectangular area (70 cm wide, 90 cm long and 
60 cm high); 63 squares (10/10) were drawn with black lines on the 
white floor of the field which was brightly illuminated from the top 
(500 lux). Three events were recorded for 5 min: (a) the latency (s) to 
move out from the center of the open field where the animal was 
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Fig. 1. Time course of the effects induced by i.c.v. administration of 
nociceptin/orphanin FQ in mice on the spontaneous motor activity 
in absence or presence of naloxone (0.1 mg/kg, s.c). Results are ex-
pressed as means ± SEM (« = 8-10 mice for each group). Sponta-
neous motor activity was recorded in an automated activity monitor 
system containing photoelectric detectors. During the test, the mice 
cut the photoelectric beams resulting in an impulse. The number of 
impulses was recorded every 5 min for 30 min. **P<0 .01 com-
pared to control group (Newman-Keuls test). 
placed and to cross two squares; (b) locomotion scored by the num-
ber of squares crossed; (c) the total number of rears. Spontaneous 
motor activity was recorded in an automated activity monitor system 
containing photoelectric detectors. During the test, the mice cut the 
photoelectric beams resulting in an impulse. The total number of 
impulses was recorded every 5 min for 90 min. The experiment was 
performed in a quiet and dimly illuminated room (50 lux). 
2.5. Analysis of data 
Statistical analysis was carried out by a 1-way analysis of variance 
(ANOVA) followed by Dunnett's t test for dose-response curves or 
Newman-Keuls test for multiple comparisons. The level of significance 
was set at P < 0.05. 
3. Results and discussion 
Intracerebroventricular administration of nociceptin/orpha-
nin F Q induced a severe reduction in spontaneous motor ac-
tivity observed in an automated activity monitor system. In-
deed, i.c.v. administration of the heptadecapeptide (1 nmol) 
decreased the vertical and horizontal activity of mice for 
about 15 min, which was not modified in presence of naloxone 
(Fig. 1). Moreover, a long-lasting hypolocomotor effect was 
recorded when nociceptin/orphanin F Q was administered at a 
higher dose (10 nmol) (Fig. 1). Except for a complete loss of 
20 min 
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O Noci/OFQ (0.1 nmol) 
• Noci/OFQ (0.1 nmol) + Best +1-24.15 
A Noci/OFQ (1 nmol) 
Δ Noci/OFQ (1 nmol) + Best + 1-24.15 
Fig. 2. Effects of bestaun (Best, 10 μg) and of the selective inhibitor 
of endopeptidase 24.15 (1-24.15, 1 μg) on the effects induced by 
i.c.v. administration of nociceptin/orphanin FQ (Noci/OFQ, 1 nmol) 
on spontaneous motor activity. Results are expressed as means 
± SEM (n = 8-10 mice for each group). Spontaneous motor activity 
was recorded in an automated activity monitor system containing 
photoelectric detectors. During the test, the mice cut the photoelec-
tric beams resulting in an impulse. The number of impulses was re-
corded every 5 min for 20 min. * P < 0 . 0 5 and **P<0 .01 com-
pared to control group; * Ä P < 0 . 0 1 compared to nociceptin/ 
orphanin FQ treated group (Newman-Keuls test). 
muscular tone observed following i.c.v. administration of the 
heptadecapeptide (10 nmol and 100 nmol) in all mice, no 
apparent toxic effect was observed. Animals recovered a mo-
tor activity similar to that of the control group ~ 80 min after 
i.c.v. administration (data not shown). These results have been 
confirmed in the open field, where a very strong increase of 
the latency time was observed, as a reduction of the number 
of squares crossed and number of rearings (Table 1). 
In a previous study it has been shown that two metallopep-
tidases are involved in the nociceptin/orphanin F Q metabo-
lism [16]. Both these enzymes, A P N and endopeptidase 24.15 
contain the typical sequence HExxH which has been found in 
numerous other zinc endopeptidases. The membrane-bound 
A P N removes the N-terminal amino acid of protein and pep-
tide substrates. This enzyme is mainly located in the small 
intestinal and kidney brush borders, but also found in lung, 
liver, primary cultures of fibroblasts and brain, where A P N 
has been found to be involved in the degradation of neuro-
peptides (review in [15]). Several studies suggest that endopep-
tidase 24.15 is a cytosolic enzyme with a minor membrane-
associated component (10-20% of total activity) [18], which 
Table 1 
Behavioral analysis of nociceptin/orphanin FQ injected i.c.v. 15 min before the open field 
Control 
1 pmol 
10 pmol 
100 pmol 
1 nmol 
Latency time(s) 
2.7 ± 0.5 
2.8 ± 0.7 
6.8 ± 2.3 
10.7 ± 2.4 
204.3 ±42.1** 
Number of squares crossed 
375.0 ±37.0 
322.9 ±45.3 
347.5 ±41.9 
335.0 ±38.8 
23.5 ±10.2** 
Events were recorded for 5 min. 
Values are mean ± SEM (n = 8-10/group). 
**i><0.01 as compared to control group (Dunnett's t test). 
Number of rearing 
31.2±2.9 
26.8 ±3.4 
27.2 ±3.5 
25.1 ±2.25 
4.3 ±3.1** 
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Fig. 3. Effects of bestatin (Best, 10 μg) and/or of the selective inhib-
itor of endopeptidase 24.15 (1-24.15, 1 μg) on the effects induced by 
i.c.v. administration of nociceptin/orphanin FQ (OFQ, 1 nmol) on 
spontaneous motor activity. Results are expressed as means ± SEM 
(« = 8-10 mice for each group). Spontaneous motor activity was re-
corded in an automated activity monitor system containing photo-
electric detectors. During the test, the mice cut the photoelectric 
beams resulting in an impulse. The number of impulses was re-
corded for 5 min, 10 min after nociceptin/orphanin FQ administra-
tion. *P < 0.05 (Newman-Keuls test). 
could account for the involvement of this peptidase in the in 
vivo metabolism of several neuropeptides [19]. A P N and en-
dopeptidase 24.15 have been shown to hydrolyse nociceptin/ 
orphanin F Q in vitro essentially at the P h e ^ G l y 2 , and A l a 7 -
Arg8 bonds, respectively, generating the metabolites G l y 2 -
Gln1 7 and P h e ^ A l a 7 [16]. At all doses tested, including con-
centrations 10 times higher (10 nmol) than those used for 
nociceptin/orphanin F Q , the metabolite peptides Gly 2 -Gln 1 7 
and P h e ^ A l a 7 were found unable to modify the spontaneous 
motor activity (data not shown). These results are in agree-
ment with structure-activity relationship studies, which have 
demonstrated that the des-Phe nociceptin/orphanin F Q , 
Gly 2 -Gln 1 7 has a 1000 times lower affinity and biological 
activity than its parent compound [20] and that the N-ter-
minal part extending up to position 8 plays a critical role 
for recognition and activation of the O R L i receptor [20,21]. 
Thus, as for other neuropeptides, interruption of the re-
sponses induced by nociceptin/orphanin F Q is ensured by 
membrane-bound enzymes which cleave the peptide into in-
active fragments. Several years ago, the characterization of 
A P N and neutral endopeptidase 24.11 (NEP), followed by 
the design of selective inhibitors have been, and will continue 
to be, of great value in determining the role of endogenous 
enkephalins (review in [15]). Therefore to achieve a better 
understanding of the physiological role of nociceptin/orphanin 
F Q , selective inhibitors of the heptadecapeptide metabolism 
were co-administered. In contrast to N E P / A P N inhibitors, 
which have an intrinsic opioidergic action [22], aminopepti-
dase and endopeptidase 24.15 inhibitors alone, or in associa-
tion, did not induce pharmacological effects after central ad-
ministration, indicating that there is little or no tonic 
participation of endogenous nociceptin/orphanin F Q in the 
behaviours measured (Figs. 2 and 3). However, a strong po-
tentiation of the hypolocomotor effect induced by i.c.v. ad-
ministration of the exogenous heptadecapeptide in the motor 
activity test was observed (Figs. 2 and 3) in the presence of the 
association of the aminopeptidase inhibitor, bestatin and the 
selective endopeptidase 24.15 inhibitor, Ζ - ^ ^ Ρ Ι ι ε Ψ -
(P0 2CH 2 ) (L,D)Ala-Arg-Phe [23]. On the other hand, due to 
the complementary role of endopeptidase 24.15 and amino-
peptidase in the nociceptin/orphanin F Q metabolism [16], se-
lective inhibition of only one of these peptidases did not give a 
significant effect (Fig. 3). This has already been observed in 
the case of enkephalins which are metabolized by the conco-
mitant action of neutral endopeptidase 24.11 and A P N (re-
view in [15]). 
In conclusion, the involvement of aminopeptidase and en-
dopeptidase 24.15 in nociceptin/orphanin F Q metabolism 
demonstrated on brain cortical slices [16] has been confirmed 
in vivo by the use of selective inhibitors. The use of peptidase 
inhibitors could permit a better understanding of the physio-
logical role of nociceptin/orphanin FQ. 
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